Advertisement

Drug dosage in renal failure

  • Ali J. Olyaei
  • William M. Bennett

Evolution within the field of dialysis and advances in surgical procedures providing for superior access for shunt placement have made it possible to treat patients with end-stage renal disease with dialysis therapy for more than 50 years. Improved pharmacotherapy of pre- and post- dialysis has also contributed to these remarkable advancements. Drug therapy is also evolving. Health care provider for patients with renal diseases needs to understand the latest drug therapy and ensure appropriateness of therapy in each individual patient [1].

Renal insufficiency and dialysis alter the pharmacokinetics and pharmacodynamics of most commonly used drugs. Of note, an average of eight different classes of drugs per patient are prescribed in patients with renal failure. In comparison to the general population, patients with renal insufficiency experience significantly more adverse drug reactions. Therefore, clinicians caring for these patients must be familiar with the pharmacokinetic behavior of each agent and of the impact of renal failure on the drug elimination process. Understanding the time course of pharmacotherapy is based on knowledge of the relationship between drug concentration and effect. Drugs act by affecting biochemical and physiological processes in the body. Most drugs act at specific receptors but may produce multiple effects because of the location of the receptor in various organs. Knowledge of these properties helps to predict the behavior of a drug in the body and is an important guide in the selection of appropriate doses and dosage intervals.

Keywords

Renal Failure Renal Replacement Therapy Drug Level Therapeutic Drug Monitoring Continuous Renal Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Winters ME, Basic clinical pharmacokinetics. Winter ME, Applied Therapeutic Inc. Vancouver, WA 1994.Google Scholar
  2. 2.
    Zhang Y. Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics. 40(3):159-68, 2001CrossRefPubMedGoogle Scholar
  3. 3.
    Olyaei AJ, Bennett WM. “The Effect of Renal Failure on Drug Handling”. Oxford Textbook of Critical Care, 1996.Google Scholar
  4. 4.
    Benedetti P. de Lalla F. Antibiotic therapy in acute renal failure. Contributions to Nephrology. (132):136-45, 2001.CrossRefGoogle Scholar
  5. 5.
    Olyaei AJ, deMattos AM, Bennett WM. “Prescribing Drugs in Renal Failure”. Brenner and Rector’s, The Kidney, 2000.Google Scholar
  6. 6.
    Olyaei AJ, deMattos AM, Bennett WM. “Drug-drug Interaction and most Commonly Used Drug in Transplant Recipients” . Primer on Transplantation, American Society of Transplantation. 2000Google Scholar
  7. 7.
    Olyaei AJ “ Drug Dosing in Renal Failure ” in Treatment Strategies In Nephrology and Hypertension. By Bennett 1st edition. PocketMedicine.com Inc 2001Google Scholar
  8. 8.
    Olyaei AJ, deMattos AM, Bennett WM “Principle of Drug Usage in Dialysis Patients” Dialysis Therapy, Hanley & Belfus Inc. Medical Publishers. May 2001Google Scholar
  9. 9.
    Olyaei AJ, de Mattos, Bennett WM, Drug usage in dialysis patients. In: Nissenson AR, Fine RN, Gentile DE, eds. Clinical dialysis.Norwalk, NJ: Appleton and Lange; 2001.Google Scholar
  10. 10.
    Bennett WM. Guide to drug dosage in renal failure. In: Speight TM, Holford N, eds. Avery’s drug treatment, 4th edn. Auckland:ADIS International; 1997:1725-92.Google Scholar
  11. 11.
    Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter?. Current Opinion in Critical Care 2001:7: 401-408.CrossRefPubMedGoogle Scholar
  12. 12.
    Livornese LL, Jr., Slavin D, Benz RL, Ingerman MJ, Santoro J. Use of antibacterial agents in renal failure. Infectious Disease Clinics of North America 2001:15: 983-1002.CrossRefPubMedGoogle Scholar
  13. 13.
    Chertow GM, Lee J, Kuperman GJ et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001:286: 2839-2844.CrossRefPubMedGoogle Scholar
  14. 14.
    Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiologica Scandinavica 2001:45: 929-934.CrossRefPubMedGoogle Scholar
  15. 15.
    Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. [Review] [47 refs]. Kidney International 2001:60: 821-830.CrossRefPubMedGoogle Scholar
  16. 16.
    Subach RA, Marx MA. Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics. Advances in Renal Replacement Therapy 1998:5: 141-147.PubMedGoogle Scholar
  17. 17.
    Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Annals of Pharmacotherapy 1998:32: 362-375.CrossRefPubMedGoogle Scholar
  18. 18.
    Joos B, Schmidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrology Dialysis Transplantation 1996:11: 1582-1585.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ali J. Olyaei
    • William M. Bennett

      There are no affiliations available

      Personalised recommendations